Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Neurologic complications in patients with inflammatory bowel disease: Increasing relevance in the era of biologics.
Shifting imaging targets in multiple sclerosis: From inflammation to neurodegeneration.
Immune modulating peptides for the treatment and suppression of multiple sclerosis.
A genome-wide association study in progressive multiple sclerosis.
Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis.
ICV-transplanted human glial precursor cells are short-lived yet exert immunomodulatory effects in mice with EAE.
Graves' disease after treatment with Alemtuzumab for multiple sclerosis.
Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory.
Sublime Microglia: Expanding Roles for the Guardians of the CNS.
Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo.
Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.
Multiple sclerosis-associated retrovirus (MSRV) in Sardinian MS patients.
The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.
Immune cell trafficking from the brain maintains CNS immune tolerance.
Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes.
Non-lesional white matter changes in pediatric multiple sclerosis and monophasic demyelinating disorders.
Recommendations for diagnosis and management of multiple sclerosis.
Plasmacytoid dendritic cells and immunotherapy in multiple sclerosis.
JC viremia in natalizumab-treated patients with multiple sclerosis.
No excess of mitochondrial DNA deletions within muscle in progressive multiple sclerosis.
Distinctive structural and functional MRI footprint for cognitive dysfunction in pediatric MS?
Self-Reported Fatigue and Energy Cost During Walking Are Not Related in Patients With Multiple Sclerosis.
Capture-Recapture as a Potentially Useful Procedure for Assessing Prevalence of Multiple Sclerosis: Methodologic Exercise Using Portuguese Data.
Intraventricularly injected Olig2-NSCs attenuate established relapsing-remitting EAE in mice.
No Association Between Conventional Brain MR Imaging and Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis.
Pages
« first
‹ previous
…
174
175
176
177
178
179
180
181
182
…
next ›
last »